US5140012A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Method for preventing onset of restenosis after angioplasty employing pravastatin
Assignee: ER Squibb and Sons LLC
•
Filing: 1990-05-31
•
Granted: 1992-08-18
•
Expires: 2010-05-31
Abstract
Abstract A method is provided for preventing or reducing the risk of restenosis following angioplasty by administering pravastatin alone or in combination with an ACE inhibitor such as captopril or ceranapril, prior to, during and/or after angioplasty.
Inventors
- 👤 Mark E. McGovern
- 👤 Miguel A. Ondetti
- 👤 Henry Y. Pan
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 03:30
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/075; A61K31/21; A61K31/215; A61K31/22; A61K31/33; A61K31/395; A61K31/40; A61K31/401; A61K45/00; A61K45/06; A61P; A61P43/00; A61P9/00; A61P9/08; A61P9/10
Claims Analysis
Total Claims: 18
Claim 1
Independent Claim
29 words
A method for preventing or reducing the risk of restenosis following angioplasty, which comprises administering to a mammalian specie in need of such treatment an effective amount of pravastatin.
Claim 2
Independent Claim
29 words
A method for preventing or reducing the risk of restenosis following angioplasty, which comprises administering to a mammalian specie in need of such treatment an effective amount of pravastatin.
Claim 3
Dependent Claim
29 words
The method as defined in claim 1 wherein said pravastatin is administered in single or divided doses of from about 1 to about 2000 mg/one to four times daily.
Claim 4
Dependent Claim
29 words
The method as defined in claim 1 wherein the pravastatin is administered in single or divided doses of from about 4 to about 200 mg/one to four times daily.
Claim 5
Dependent Claim
15 words
The method as defined in claim 1 wherein the pravastatin is administered prior to angioplasty.
Claim 6
Dependent Claim
14 words
The method as defined in claim 1 wherein the pravastatin is administered during angioplasty.
Claim 7
Dependent Claim
14 words
The method as defined in claim 1 wherein the pravastatin is administered after angioplasty.
Claim 8
Dependent Claim
17 words
The method as defined in claim 1 wherein pravastatin is administered in combination with an ACE inhibitor.
Claim 9
Dependent Claim
18 words
The method as defined in claim 7 wherein the angiotensin converting enzyme inhibitor is a substituted proline derivative.
Claim 10
Dependent Claim
23 words
The method as defined in claim 7 wherein said angiotensin converting enzyme inhibitor includes a mercapto moiety and is a substituted proline derivative.
Claim 11
Dependent Claim
18 words
The method as defined in claim 7 wherein said angiotensin converting enzyme inhibitor is a substituted proline derivative.
Claim 12
Dependent Claim
22 words
The method as defined in claim 7 wherein said angiotensin converting enzyme inhibitor is captopril, zofenopril, enalapril, cernapril, fosinopril, lisinopril or fentiapril.
Claim 13
Dependent Claim
50 words
The method as defined in claim 7 wherein the angiotensin converting enzyme inhibitor is a phosphonate substituted amino or imino acid or salt thereof, a proline derivative, a substituted proline derivative, a mercaptoacyl derivative of a substituted proline, a carboxyalkyl dipeptide derivative, a phosphinylalkanoyl proline derivative or a phosphonamidate derivative.
Claim 14
Dependent Claim
18 words
The method as defined in claim 12 wherein said angiotensin converting enzyme inhibitor is a carboxyalkyl dipeptide derivative.
Claim 15
Dependent Claim
32 words
The method as defined in claim 7 wherein said angiotensin converting enzyme inhibitor is a phosphinylalkanoyl proline derivative, a phosphoramidate derivative, or a phosphonate substituted amino or imino acid or salt thereof.
Claim 16
Dependent Claim
33 words
The method as defined in claim 7 wherein the pravastatin is present in a weight ratio to said ACE inhibitor of the of within the range of from about 0.001:1 to about 1000:1.
Claim 17
Dependent Claim
32 words
The method as defined in claim 7 wherein said angiotensin converting enzyme inhibitor is administered in single or divided doses of from about 0.1 to about 500 mg/one to four times daily.
Claim 18
Dependent Claim
16 words
The method as defined in claim 7 wherein the ACE inhibitor is captopril, fosinopril or ceranapril.
References Cited (Backward Citations)
US4346227A
Cited
EP0219782A2
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1995-08-18 | 1996-02-17 | 1996-08-18 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1999-08-18 | 2000-02-17 | 2000-08-18 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2003-08-18 | 2004-02-17 | 2004-08-18 | $7700.00 | Window Closed / Lapsed |